Denosumab biosimilar (LY06006) in Chinese postmenopausal osteoporotic women: A randomized, double-blind, placebo-controlled, multicenter phase III study

OBJECTIVES: This study assessed the efficacy, safety, pharmacokinetics (PK), and immunogenicity profiles of a denosumab biosimilar (LY06006) in Chinese postmenopausal osteoporotic women with a high risk of fracture. METHODS: In this multicenter, randomized, double-blind, placebo-controlled, phase 3...

Descripción completa

Detalles Bibliográficos
Autores principales: Gu, Jiemei, Zhang, Hao, Xue, Qingyun, Wang, Li, Cheng, Zhifeng, Zhang, Yawei, Li, Qifu, Yuan, Lingqing, Li, Yukun, Dong, Jin, Huo, Yanan, Tang, Xin, Hu, Ling, Wang, Xinjia, Hua, Fei, Shen, Lin, Cheng, Jinluo, Zhou, Huimin, Xu, Youjia, Yang, Tao, Wang, Chuansuo, Xu, Jin, Shen, Jie, Zhang, Ying, Zhang, Xiaomei, Hong, Dun, Guan, Xiaoling, Xiao, Xinhua, Wang, Guang, Liu, Yonghua, Fu, Liujun, Chen, Jianting, Cheng, Xigao, Ding, Yue, Liu, Lijun, Yao, Qi, Zhang, Xinchao, Li, Lixin, Zhang, Panjun, Deng, Chunying, Jiang, Chengyan, You, Li, Wang, Kai, Zhang, Shimin, Xiao, Jianzhong, Liu, Wei, Du, Xiaohong, Shang, Xianwen, Pan, Tianrong, Lei, Chen, Guo, Shuren, Zhang, Zhenlin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Chinese Speaking Orthopaedic Society 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9633870/
https://www.ncbi.nlm.nih.gov/pubmed/36381249
http://dx.doi.org/10.1016/j.jot.2022.06.007

Ejemplares similares

Ejemplares similares